Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Jazz Pharmaceuticals PLC (JAZZ) vs Summit Therapeutics PLC (SMMT)

Jazz Pharmaceuticals PLC and Summit Therapeutics PLC are both Biotechnology companies. Jazz Pharmaceuticals PLC is the larger, with a market value of $15.3B against $13.1B — 1.2× the size. Summit Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Jazz Pharmaceuticals PLC trades at 15.6×. Jazz Pharmaceuticals PLC grew revenue faster over the last twelve months: 12.6% against −61.0%. Jazz Pharmaceuticals PLC has the higher net margin (20.5% vs 0.00%) and the higher return on invested capital (8.06% vs 0.00%). Across the 18 metrics below, Jazz Pharmaceuticals PLC leads on 14 and Summit Therapeutics PLC on 4.

Valuation

Metric JAZZ SMMT Biotechnology median
P/E 15.60 n/m 7.88
P/S 3.27 17,230.45 11.47
P/B 3.13 19.28 2.52
Price to free cash flow 10.62 n/m 21.16
EV/EBITDA 10.64 n/m 0.74
EV/Sales 3.74 16,392.16 10.73
Earnings yield 6.41% (7.17%) (28.84%)
Free cash flow yield 9.42% (3.79%) (23.03%)

Profitability

Metric JAZZ SMMT Biotechnology median
Gross margin 88.42% 100.00% 65.16%
Operating margin 19.49% 0.00% 0.00%
Net margin 20.45% 0.00% 0.00%
Free cash flow margin 30.79% 0.00% 0.00%
Return on equity 22.11% (192.50%) (57.72%)
Return on assets 8.54% (159.09%) (49.22%)
Return on invested capital 8.06% 0.00% 0.00%

Growth

Metric JAZZ SMMT Biotechnology median
Revenue growth (TTM) 12.59% (61.03%) 5.64%
EPS growth (last fiscal year) (167.51%) (364.52%) —
Revenue growth, 5-year CAGR 12.54% (46.49%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric JAZZ SMMT Biotechnology median
Debt to equity 0.91 0.00 0.00
Current ratio 1.78 6.96 4.73
Net debt to EBITDA 10.96 0.65 0.96

Dividend

Metric JAZZ SMMT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric JAZZ SMMT Biotechnology median
Market cap 15.34b 13.12b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack